Novartis Korea said that it has affirmed the efficacy of Tasigna, a chronic myelogenous leukemia (CML) treatment, through the result from its 10 years follow- up of the ENESTnd trial.
|Novartis' chronic myelogenous leukemia treatment Tasigna|
Clinical results showed that more than eight out of 10 patients treated with Tasigna maintained a major molecular response (MMR), and seven out of 10 patients responded to a deep molecular response (DMR), a prerequisite for treatment-free remission (TFR), increasing the likelihood of success of full care.
Also, the Tasigna treatment group experienced less than half of the cases of acute and accelerated disease compared to the control group.
The full results were presented during the recent annual conference of 61st American Society of Hematology (ASH).
With the trial, Tasigna has become the only second-generation tyrosine kinase-targeted anticancer drug (2G TKI) that has 10-year clinical data.
"The results show that Tasigna's excellent effects last for a long time," said Professor Kim Dong-wook at St. Mary's Seoul Hospital, who participated in the trial. "Notably, it showed an excellent effect on achieving DMR and increased the possibility of TFR of CML patients."
As the first 10-year clinical results of 2G TKIs are published, we can now secure and use data on the effectiveness and safety sufficient for 2G TKI to develop various clinical treatment technologies, Kim added.
<© Korea Biomedical Review, All rights reserved.>